Tag Archives: Adaptimmune Therapeutics

Raymond James Keeps a Buy Rating on Adaptimmune Therapeutics

Raymond James analyst Reni Benjamin maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on March 16 and set a price target of $20. The company’s shares closed on Friday at $12.44, close to its 52-week high of $13.41. Benjamin

Raymond James Believes Adaptimmune Therapeutics (NASDAQ: ADAP) Won’t Stop Here

Raymond James analyst Reni Benjamin maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on March 16 and set a price target of $20. The company’s shares closed on Friday at $12.44, close to its 52-week high of $13.41. Benjamin

Raymond James Remains a Buy on Adaptimmune Therapeutics

Raymond James analyst Reni Benjamin maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) today. The company’s shares closed yesterday at $12.36, close to its 52-week high of $13.41. Benjamin wrote: “We are maintaining our Outperform rating on Adaptimmune Therapeutics.

Adaptimmune Therapeutics Gets a Buy Rating from Raymond James

In a report released today, Reni Benjamin from Raymond James maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP), with a price target of $20. The company’s shares opened today at $11.10. Benjamin observed: “We are maintaining our Outperform rating

SunTrust Robinson Reiterates Their Buy Rating on Adaptimmune Therapeutics

In a report released today, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP), with a price target of $10. The company’s shares closed yesterday at $8.10. According to TipRanks.com, Lawson is a 4-star analyst

SunTrust Robinson Reiterates a Buy Rating on Adaptimmune Therapeutics

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on October 9 and set a price target of $10. The company’s shares opened today at $7.88. According to TipRanks.com, Lawson is a 5-star analyst with